14 Best Biotech Stocks To Buy According To Hedge Funds

Published on May 25, 2023 at 4:03 am by Ramish Cheema in Hedge Funds, News

In this piece, we will take a look at 14 best biotechnology stocks to buy according to hedge funds. For more stocks, head on over to 5 Best Biotech Stocks To Buy According To Hedge Funds.

Biotechnology is one of the hottest sectors these days. A handful of industries, such as space exploration, artificial intelligence, and biotechnology, are making rapid leaps forward. For biotechnology, the greatest stimulus has been the coronavirus pandemic as the industry was solely responsible for bailing humanity out of the devastating crisis.

Simply put, biotechnology is the use of biological raw materials to make vaccines and other products with them. This is in sharp contrast to traditional pharmaceutical applications that use plants and other raw materials to make medicines. Through biotechnology, firms such as Pfizer Inc. (NYSE:PFE), Moderna, Inc. (NASDAQ:MRNA), and BioNTech SE (NASDAQ:BNTX) were able to develop the revolutionary messenger ribonucleic acid (mRNA) vaccines that were able to effectively reduce the severity of the disease. mRNA is simply a storage vehicle for instructions that program cells to produce certain kinds of proteins. For the coronavirus vaccine, these proteins fight the virus molecules and protect the recipient against the disease.

Apart from mRNA, there are dozen of other applications for biotechnology as well which are not limited to human health either. The sector is responsible for having saved countless lives over the past few decades simply by enabling the production of insulin. While insulin was initially produced by pigs, naturally there aren’t enough pigs in the world to meet the needs of all diabetics. To solve this problem, biotechnology enabled insulin makers to clone the human gene responsible for making insulin in bacteria and produce as much of the life saving substance as needed. Apart from insulin, other sectors such as gene therapy, vaccine vegetables, and diagnosis are other areas that are a crucial part of the biotechnology industry.

Moving forward from human health, other areas benefiting from biotechnology are chemicals production and agriculture as organic compounds enable significant streamlining of these industries. These use cases naturally end up leading to stunning valuations of the industry. For instance, a research report from Grand View Research outlines that the biotechnology industry was worth a whopping $1.37 trillion last year. From 2023 until 2030, the industry is slated to grow at a compounded annual growth rate (CAGR) of 13.96% – a rather high rate when we consider the large size of the sector. This growth rate can ensure that the biotechnology industry is worth $3.88 trillion by the end of the forecast period. Grand View Research adds that one of the biggest sectors in the market was DNA sequencing, as it accounted for 16.5% of the market and grew due to the dropping costs of this technology. In terms of growth, the research firm believes that one of the fastest growing segments will be nanobiotechnology, which is expected to outpace the broader market in growth by increasing by 14.87%. Application wise, healthcare was unsurprisingly the largest sector as it represented more than half of the total market.

One major drug in the biotechnology industry that is making waves these days is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s DUPIXENT. This is a treatment for patients with chronic obstructive pulmonary disorder (COP) – a devastating disease stemming from lung damage mostly in former smokers. At the firm’s latest earnings call, management shared the remarkable impact that this drug is making, as they outlined:

The first quarter of 2023 delivered multiple significant milestones for Regeneron and for our collaborations, from the positive DUPIXENT Phase III COPD data to progress in our oncology pipeline, as well as exciting new landmarks from our genetic medicines programs. Starting with DUPIXENT. In March, together with our Sanofi collaborators, we announced that DUPIXENT was the first immune mechanism of action treatment to produce statistically significant and clinically meaningful results in a Phase III trial for COPD in over a decade. Our BOREAS trial enrolled COPD patients with moderate to severe disease and evidence of type 2 inflammation. DUPIXENT-treated patients demonstrated a clinically meaningful 30% reduction in exacerbations, a significant improvement in lung function as well as quality of life benefits: an impressive trifecta in a potential paradigm-changing treatment for this deadly disease.

We are looking forward to presenting the detailed BOREAS results in a late-breaking presentation at the upcoming American Thoracic Society Meeting later this month. We also plan to discuss these exciting results with regulatory authorities and expect to report results mid next year for the replicate Phase III NOTUS study. I would remind you that we are also trying to address an overlapping COPD population with our IL-33 antibody, which is in Phase III studies based on positive Phase II proof-of-concept data. This approach is further supported by genetic analysis from our Regeneron Genetics Center, which demonstrated association of loss of function in IL-33 with reduced COPD risk. Similar genetic analysis supported the role for a DUPIXENT benefit in COPD.

With these impressive details in mind, let’s take a look at some of the top biotechnology stocks that hedge funds are piling into, out of which the top picks are Merck & Co., Inc. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), and AbbVie Inc. (NYSE:ABBV).

Photo by National Cancer Institute on Unsplash

Our Methodology

To compile our list of the best biotechnology stocks according to hedge funds, we first made a list of all major biotechnology companies. Then, the number of hedge fund investors that had owned their shares was determined through Insider Monkey’s first quarter of 2023 survey, and the top fifteen biotechnology companies according to hedge funds are listed below.

Best Biotech Stocks To Buy According To Hedge Funds

14. Seagen Inc. (NASDAQ:SGEN)

Number of Hedge Fund Investors In Q1 2023: 47

Seagen Inc. (NASDAQ:SGEN) is an American company headquartered in Bothell, Washington. The firm primarily focuses on developing treatments for cancer. Its products target several kinds of cancers such as lymphoma, breast cancer, cervical cancer, and more.

After digging through 943 hedge funds for their first quarter of 2023 investments, Insider Monkey discovered that 47 had invested in Seagen Inc. (NASDAQ:SGEN). Along with Merck & Co., Inc. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), and AbbVie Inc. (NYSE:ABBV), it is a favorite hedge fund biotech stock pick.

13. United Therapeutics Corporation (NASDAQ:UTHR)

Number of Hedge Fund Investors In Q1 2023: 51

United Therapeutics Corporation (NASDAQ:UTHR) focuses on several different diseases such as hypertension, lung disorders, and fibrosis. The firm was set up in 1996 and it is headquartered in Silver Spring, Maryland.

Insider Monkey’s first quarter of 2023 survey revealed that 51 had bought a stake in the company. Out of these United Therapeutics Corporation (NASDAQ:UTHR)’s largest hedge fund investor is Kurt Von Emster’s VenBio Select Advisor since it owns 2.8 million shares that are worth $642 million.

12. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Number of Hedge Fund Investors In Q1 2023: 54

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) markets different products such as medicines for inflammatory conditions, blindness, cancer, heart diseases, and others. The firm is based in 1988 and it operates out of Tarrytown, New York.

54 of the 943 hedge funds profiled by Insider Monkey for their Q1 2023 shareholdings had bought Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s shares. The firm’s largest hedge fund investor is Ken Griffin’s Citadel Investment Group with a $239 million stake.

11. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Number of Hedge Fund Investors In Q1 2023: 56

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is based in San Rafael, California. It develops enzyme replacement therapies, purified proteins, and treatments for metabolic diseases.

As of March 2023, 56 of the 943 hedge funds part of Insider Monkey’s database had held a stake in the firm. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)’s largest investor in our database is Kurt Von Emster’s VenBio Select Advisor since it has a $383 million investment.

10. Amgen Inc. (NASDAQ:AMGN)

Number of Hedge Fund Investors In Q1 2023: 57

Amgen Inc. (NASDAQ:AMGN) is one of the older companies on our list since it was set up in 1983. It is also one of the most successful biotechnology companies, having developed treatments for a laundry list of diseases including anemia, migraine, leukemia, osteoporosis, cancer, and others.

By the end of this year’s first quarter, 57 investors out of the 943 profiled by Insider Monkey had bought Amgen Inc. (NASDAQ:AMGN)’s shares. The firm’s largest shareholder is John Overdeck and David Siegel’s Two Sigma Advisors with a $404 million stake that comes through 1.6 million shares.

9. IQVIA Holdings Inc. (NYSE:IQV)

Number of Hedge Fund Investors In Q1 2023: 60

IQVIA Holdings Inc. (NYSE:IQV) is a back end biotechnology company based in Durham, North Carolina. The firm provides analytics, management, and monitoring services to the biotechnology industry.

After digging through 943 hedge fund portfolios for 2023’s March quarter, Insider Monkey discovered that 60 had held a stake in the firm. IQVIA Holdings Inc. (NYSE:IQV)’s largest investor is Thomas Steyer’s Farallon Capital since it has a $638 million stake.

8. Gilead Sciences, Inc. (NASDAQ:GILD)

Number of Hedge Fund Investors In Q1 2023: 60

Gilead Sciences, Inc. (NASDAQ:GILD) makes vaccines and treatments for the coronavirus, hepatitis, and other diseases. It is headquartered in Foster City, California.

60 of the 943 hedge funds part of Insider Monkey’s database had invested in Gilead Sciences, Inc. (NASDAQ:GILD) during Q1 2023. Out of these, the firm’s largest investor is Jim Simons’ Renaissance Technologies with an $878 million stake.

7. Biogen Inc. (NASDAQ:BIIB)

Number of Hedge Fund Investors In Q1 2023: 67

Biogen Inc. (NASDAQ:BIIB) develops treatments for neurological diseases. It was set up in 1978 and operates out of Cambridge, Massachusetts.

As of March 2023, 67 of the 943 hedge funds studied by Insider Monkey had bought the firm’s shares. Biogen Inc. (NASDAQ:BIIB)’s largest hedge fund shareholder is D.E. Shaw’s D E Shaw through a $370 million investment.

6. Bristol-Myers Squibb Company (NYSE:BMY)

Number of Hedge Fund Investors In Q1 2023: 69

Bristol-Myers Squibb Company (NYSE:BMY) is one of the largest biopharmaceutical companies in the world. Its products target cancer, myeloma, arthritis, and other diseases.

Insider Monkey’s first quarter of 2023 survey of 943 hedge funds revealed that 69 had invested in Bristol-Myers Squibb Company (NYSE:BMY). Its largest investor is Richard S. Pzena’s Pzena Investment Management with a $312 million stake.

Merck & Co., Inc. (NYSE:MRK), Bristol-Myers Squibb Company (NYSE:BMY), Johnson & Johnson (NYSE:JNJ), and AbbVie Inc. (NYSE:ABBV) are some biotechnology stocks finding favor with the hedge funds.

Click to continue reading and see the 5 Best Biotech Stocks To Buy According To Hedge Funds.

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on June 23, 2025 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

AI is eating the world—and the machines behind it are ravenous.

Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink.

Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and building the digital future. But there’s one urgent question few are asking:

Where will all of that energy come from?

AI is the most electricity-hungry technology ever invented. Each data center powering large language models like ChatGPT consumes as much energy as a small city. And it’s about to get worse.

Even Sam Altman, the founder of OpenAI, issued a stark warning:

“The future of AI depends on an energy breakthrough.”

Elon Musk was even more blunt:

“AI will run out of electricity by next year.”

As the world chases faster, smarter machines, a hidden crisis is emerging behind the scenes. Power grids are strained. Electricity prices are rising. Utilities are scrambling to expand capacity.

And that’s where the real opportunity lies…

One little-known company—almost entirely overlooked by most AI investors—could be the ultimate backdoor play. It’s not a chipmaker. It’s not a cloud platform. But it might be the most important AI stock in the US owns critical energy infrastructure assets positioned to feed the coming AI energy spike.

As demand from AI data centers explodes, this company is gearing up to profit from the most valuable commodity in the digital age: electricity.

The “Toll Booth” Operator of the AI Energy Boom

It owns critical nuclear energy infrastructure assets, positioning it at the heart of America’s next-generation power strategy.
It’s one of the only global companies capable of executing large-scale, complex EPC (engineering, procurement, and construction) projects across oil, gas, renewable fuels, and industrial infrastructure.
It plays a pivotal role in U.S. LNG exportation—a sector about to explode under President Trump’s renewed “America First” energy doctrine.

Trump has made it clear: Europe and U.S. allies must buy American LNG.

And our company sits in the toll booth—collecting fees on every drop exported.

But that’s not all…

As Trump’s proposed tariffs push American manufacturers to bring their operations back home, this company will be first in line to rebuild, retrofit, and reengineer those facilities.

AI. Energy. Tariffs. Onshoring. This One Company Ties It All Together.

While the world is distracted by flashy AI tickers, a few smart investors are quietly scooping up shares of the one company powering it all from behind the scenes.

AI needs energy. Energy needs infrastructure.

And infrastructure needs a builder with experience, scale, and execution.

This company has its finger in every pie—and Wall Street is just starting to notice.

Wall Street is noticing this company also because it is quietly riding all of these tailwinds—without the sky-high valuation.

While most energy and utility firms are buried under mountains of debt and coughing up hefty interest payments just to appease bondholders…

This company is completely debt-free.

In fact, it’s sitting on a war chest of cash—equal to nearly one-third of its entire market cap.

It also owns a huge equity stake in another red-hot AI play, giving investors indirect exposure to multiple AI growth engines without paying a premium.

And here’s what the smart money has started whispering…

The Hedge Fund Secret That’s Starting to Leak Out

This stock is so off-the-radar, so absurdly undervalued, that some of the most secretive hedge fund managers in the world have begun pitching it at closed-door investment summits.

They’re sharing it quietly, away from the cameras, to rooms full of ultra-wealthy clients.

Why? Because excluding cash and investments, this company is trading at less than 7 times earnings.

And that’s for a business tied to:

The AI infrastructure supercycle
The onshoring boom driven by Trump-era tariffs
A surge in U.S. LNG exports
And a unique footprint in nuclear energy—the future of clean, reliable power

You simply won’t find another AI and energy stock this cheap… with this much upside.

This isn’t a hype stock. It’s not riding on hope.

It’s delivering real cash flows, owns critical infrastructure, and holds stakes in other major growth stories.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 100+% Return within 12 to 24 months.

We’re now offering month-to-month subscriptions with no commitments.

For a ridiculously low price of just $9.99 per month, you can unlock our in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

Access to our Detailed Report on our AI, Tariffs, and Nuclear Energy Stock with 100+% potential upside within 12 to 24 months
BONUS REPORT on our #1 AI-Robotics Stock with 10000% upside potential: Our in-depth report dives deep into our #1 AI/robotics stock’s groundbreaking technology and massive growth potential.
One New Issue of Our Premium Readership Newsletter: You will also receive one new issue per month and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.
One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149
Bonus Content: Premium access to members-only fund manager video interviews
Ad-Free Browsing: Enjoy a month of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
Lifetime Price Guarantee: Your renewal rate will always remain the same as long as your subscription is active.
30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

Insider Monkey Ads

A New Dawn is Coming to U.S. Stocks

Published on June 13, 2025 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up

14 Best Biotech Stocks To Buy According To Hedge Funds

Published on May 25, 2023 at 4:03 am by Ramish Cheema in Hedge Funds, News

Best Biotech Stocks To Buy According To Hedge Funds

14. Seagen Inc. (NASDAQ:SGEN)

13. United Therapeutics Corporation (NASDAQ:UTHR)

12. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

11. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

10. Amgen Inc. (NASDAQ:AMGN)

9. IQVIA Holdings Inc. (NYSE:IQV)

8. Gilead Sciences, Inc. (NASDAQ:GILD)

7. Biogen Inc. (NASDAQ:BIIB)

6. Bristol-Myers Squibb Company (NYSE:BMY)

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on June 23, 2025 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up:

A New Dawn is Coming to U.S. Stocks

Published on June 13, 2025 at by Insider Monkey Staff

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Premium

Log In

Sign Up

14 Best Biotech Stocks To Buy According To Hedge Funds

Published on May 25, 2023 at 4:03 am by Ramish Cheema in Hedge Funds, News

Share

Best Biotech Stocks To Buy According To Hedge Funds

14. Seagen Inc. (NASDAQ:SGEN)

13. United Therapeutics Corporation (NASDAQ:UTHR)

12. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

11. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

10. Amgen Inc. (NASDAQ:AMGN)

9. IQVIA Holdings Inc. (NYSE:IQV)

8. Gilead Sciences, Inc. (NASDAQ:GILD)

7. Biogen Inc. (NASDAQ:BIIB)

6. Bristol-Myers Squibb Company (NYSE:BMY)

Share

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on June 23, 2025 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up:

A New Dawn is Coming to U.S. Stocks

Published on June 13, 2025 at by Insider Monkey Staff